Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study

被引：0
|
作者：
Ait-Khaled, M. [1 ]
Nascimento, M. C. [1 ]
Pappa, K. A. [2 ]
Wang, R. [2 ]
Wright, J. [3 ]
Tenorio, A. R. [2 ]
Wynne, B. [2 ]
Aboud, M. [1 ]
Gartland, M. [2 ]
van Wyk, J. [1 ]
机构：
[1] ViiV Healthcare, Brentford, England
[2] ViiV Healthcare, Res Triangle Pk, NC USA
[3] GlaxoSmithKline, Stockley Pk, England
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PS7/2
引用
收藏
页码：20 / 20
页数：1
相关论文
共 18 条
  • [1] Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)
    van Wyk, J.
    Ajana, F.
    Bisshop, F.
    De Wit, S.
    Osiyemi, O.
    Portilla, J.
    Routy, J.
    Wyen, C.
    Ait-Khaled, M.
    Nascimento, M.
    Pappa, K.
    Wang, R.
    Wright, J.
    Wynne, B.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 14 - 15
  • [2] Switching to DTG/3TC Is non-inferior to continuing a TAF-based regimen at week 144: TANGO subgroup analyses
    Scholten, S.
    Ajana, F.
    Benson, P.
    Kinder, C.
    Smith, D. E.
    Olalla Sierra, J.
    Ait-Khaled, M.
    Pappa, K. A.
    Wang, R.
    Wright, J.
    Wynne, B.
    Aboud, M.
    van Wyk, J.
    Smith, K. Y.
    HIV MEDICINE, 2021, 22 : 128 - 129
  • [3] Switching to DTG+3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study)
    van Wyk, J.
    Ajana, F.
    Bisshop, F.
    De Wit, S.
    Osiyemi, Y.
    Portilla, J.
    Routy, J. -P.
    Wyen, C.
    Ait-Khaled, M.
    Nascimento, M.
    Pappa, K.
    Wang, R.
    Wright, J.
    Tenorio, A. -R.
    Wynne, B.
    Aboud, M.
    Gartland, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 102 - 103
  • [4] Switching to DTG/3TC fixed-dose combination (FDC) is noninferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks: TANGO study
    van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria-Claudia
    Pappa, Keith
    Wang, Ruolan
    Wright, Jonathan
    Wynne, Brian
    Aboud, Michael
    Smith, Kimberly
    Rubach, Martin
    INFECTION, 2021, 49 (SUPPL 1) : S13 - S13
  • [5] Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)
    Van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria-Claudia
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    Wynne, Brian
    Aboud, Michael
    Smith, Kimberly Y.
    HIV MEDICINE, 2021, 22 : 28 - 28
  • [6] Switching to DTG/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses
    Taylor, S.
    Andrade-Villanueva, J. F.
    Kaplan, R.
    Nahass, R.
    Hocqueloux, L.
    Scholten, S.
    Di Giambenedetto, S.
    Galera, C.
    Blair, L.
    Wynne, B.
    Oyee, J.
    Underwood, M.
    Curtis, L.
    Bontempo, G.
    van Wyk, J.
    HIV MEDICINE, 2021, 22 : 129 - 129
  • [7] Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA)
    Llibre, J. M.
    Alves, C.
    Cheng, C-Y
    Osiyemi, O.
    Galera, C.
    Hocqueloux, L.
    Maggiolo, F.
    Degen, O.
    Blair, E.
    Wynne, B.
    Oyee, J.
    Underwood, M.
    Curtis, L.
    Bontempo, G.
    van Wyk, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 13 - 14
  • [8] Low-level HIV replication for DTG/3TC vs TAF-based regimen in TANGO through week 144
    Wang, Ruolan
    George, Nisha
    Ait-Khaled, Mounir
    Tomlinson, Andrew
    Oyee, James
    Lutz, Thomas
    Osiyemi, Olayemi
    Gorgolas, Miguel
    Moodley, Riya
    Wynne, Brian
    Sithamparanathan, Myooran
    Underwood, Mark
    Schneider, Martha
    HIV MEDICINE, 2023, 24 : 46 - 47
  • [9] Switching from a three-drug TAF-based regimen to a two-drug DTG/3TC FDC was not associated with a higher frequency of intermittent viraemia in suppressed patients in TANGO
    Wang, R.
    Horton, J.
    Wright, J.
    Razeek, R.
    Ait-Khaled, M.
    Nascimento, M. C.
    Underwood, M.
    van Wyk, J.
    HIV MEDICINE, 2020, 21 : 22 - 22
  • [10] Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study
    van Wyk, J.
    Ait-Khaled, M.
    Santos, J.
    Scholten, S.
    Wohlfeiler, M.
    Ajana, F.
    Jones, B.
    Nascimento, M. C.
    Tenorio, A.
    Smith, D.
    Wright, J.
    Wynne, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 27 - 27
12